This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: cost

May 2010 Br J Cardiol 2010;17:s14-s15

Costs and benefits of ARBs in practice

David Taylor, Mark Davis

Abstract

This brief paper considers how such cost pressures may affect the use of angiotensin receptor blockers (ARBs) in the NHS, given that although losartan is the first drug in this class to become generic in March 2010, others will quickly follow suit. Valsartan loses patent protection in 2011, with candesartan and irbesartan following in 2012. Indications for ARB use Recent data indicate that candesartan is presently the most widely used ARB in England, accounting for almost a third of all ARB prescriptions. This is in part because it has been competitively priced compared with other ARBs. In average prescription cost terms, candesartan has in r

| Full text

July 2004 Br J Cardiol 2004;11:307-9

Is provision and funding of cardiac rehabilitation services sufficient for the achievement of the National Service Framework goals?

Ingolf Griebsch, Jackie Brown, Andrew D Beswick, Karen Rees, Robert West, Fiona Taylor, Rod Taylor, Jackie Victory, Margaret Burke, Sally Turner, Hugh Bethell, Shah Ebrahim

Abstract

No content available

| Full text
Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now